Alexion Pharmaceuticals
UEI: DKCXLGANZAN3
• CAGE: 4EXK1
Overview
Parent Awardee
Company Description
Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.
Name
Alexion Pharmaceuticals
Website
Headquarters
Boston, MA
United States
United States
Most Recent Award
July 21, 2026
Calculating
Federal contract recipient
ALEXION PHARMACEUTICALS INC
dba ALEXION PHARMACEUTICALS INC
(UEI DKCXLGANZAN3, CAGE 4EXK1)
is headquartered in Boston MA.
Its primary registered NAICS is 325412 Pharmaceutical Preparation Manufacturing.
The corporation
was founded in January 1992 and
federally registered in
May 2006.
Federal Award Analysis
Alexion Pharmaceuticals federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
ALEXION PHARMACEUTICALS INC
DBA
ALEXION PHARMACEUTICALS INC
UEI
DKCXLGANZAN3
CAGE Code
4EXK1
Primary NAICS
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Jan. 28, 1992
Initial Registration
May 30, 2006
Last Registration
April 29, 2026
Registration Activation
April 29, 2026
Registration Expiration
April 27, 2027
Fiscal Year End
December 31
Reported Entity Types
Foreign Owned
For Profit Organization
Manufacturer of Goods
For Profit Organization
Manufacturer of Goods
State of Incorporation
DE
Country of Incorporation
USA
Employees
>1500
Reported NAICS
Reported PSC
Accepts Credit Cards
No
People
Vendor contacts at Alexion Pharmaceuticals
GSA Schedules and Price Lists
- Alexion Pharmaceuticals
- PoP: 6/14/26 - 6/14/31
- Alexion Pharmaceuticals
- PoP: 3/31/18 - 6/15/26 (Ended)
- Type: Pharmaceuticals and Drugs (FSS 65 I B)
- Obligated: $3,264,817